Aprea therapeutics announces first patient dosed in acesot-1051 phase 1 trial evaluating oral wee1 inhibitor apr-1051

Apr-1051 is a highly selective and potentially best-in-class oral wee1 inhibitor phase 1 acesot-1051 clinical trial is evaluating apr-1051 as monotherapy treatment in patients with significant unmet medical need dosing of the first patient in the acesot-1051 study represents a key advancement in aprea's clinical pipeline doylestown, pa., june 17, 2024 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre) (“aprea”, or the “company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that the first patient has been dosed in the acesot-1051 phase 1 study evaluating daily oral wee1 inhibitor apr-1051 as monotherapy in advanced solid tumor patients with unmet medical need.
APR Ratings Summary
APR Quant Ranking